Key points
Tapinarof (brand name VTAMA) is a 1% steroid-free cream and the first aryl hydrocarbon receptor (AhR) modulator: it is applied once daily, does not cause skin atrophy, and so carries no limits on duration, treated area or body site — the face and folds included.
| Condition | How it helps | What human studies showed |
|---|---|---|
| Plaque psoriasis in adults | repairs the skin barrier and damps interleukin-17, the dominant inflammatory pathway in psoriasis | PSOARING 1 and 2, 1,025 adults, 12 weeks: clear or almost clear skin in 35.4% and 40.2% versus 6.0% and 6.3% on vehicle cream [1]; PSOARING 3, 40 weeks: completely clear skin in 40.9%; in those who reached it, lesions took a mean of 130 days to return after stopping [2] |
| Moderate-to-severe atopic dermatitis in adults and children from age 2 | upregulates the barrier proteins filaggrin and loricrin and damps interleukins 4 and 13 | ADORING 1 and 2, 813 patients, 8 weeks: response in 45.4% and 46.4% versus 13.9% and 18.0%, itch improved rapidly [3]; ADORING 3, 48 weeks: completely clear skin in 51.9%; in those who reached it, the first treatment-free interval averaged 79.8 days [4] |
How it helps
A steroid ointment works quickly and predictably. The problem is not efficacy — it is the built-in counter: prolonged use thins the skin, leaves striae and visible vessels, and on the face readily produces perioral dermatitis.
So the physician always draws a line: two weeks, no longer; not on the face; not over a large area. Yet psoriasis and atopic dermatitis are chronic, and treatment runs for years. That gap produced both patient steroid phobia and the biggest unfilled niche in dermatology: a non-steroidal topical that can be used for a long time and everywhere.
How it works
Tapinarof is a synthetic analogue of a stilbene produced by bacteria of the genus Photorhabdus, which live in symbiosis with nematodes. The molecule was not designed at a chemist's bench — it was found in natural material and developed into a drug.
Its target is the aryl hydrocarbon receptor (AhR), a sensor inside the cell. It evolved to read chemical signals from the environment: tryptophan breakdown products, compounds from plant food, metabolites of the skin microbiome. Through it the skin tunes two things at once — barrier strength and the level of inflammation. In psoriasis and eczema that tuning is off.
A steroid ointment acts like the main light switch: it shuts inflammation down wholesale, useful activity included. And the longer you keep it off, the more the room itself fades — that fading is skin atrophy.
Tapinarof is not a switch but a dial that restores the skin's own factory programme. By activating AhR it upregulates the barrier proteins filaggrin and loricrin — precisely the ones genetically in short supply in atopic dermatitis — while damping the inflammatory signal: interleukin-17 in psoriasis, interleukins 4 and 13 in eczema. An antioxidant response is switched on alongside.
Hence the logic of two indications at once: the barrier is repaired in both diseases, and the inflammatory pathway that dominates each one is the one turned down.
| Tapinarof | Topical steroids | Calcineurin inhibitors | PDE-4 inhibitors | |
|---|---|---|---|---|
| Steroid | No | Yes | No | No |
| Skin atrophy with long-term use | No | Yes | No | No |
| Duration limit | None | Yes | None | None |
| Face and folds | Permitted | Restricted | Permitted | Permitted |
| Burning on application | Uncommon | No | Common early on | Sometimes |
| Applications per day | Once | One to two | Twice | One to two |
| Indications | Psoriasis and atopic dermatitis | Both | Mainly atopic dermatitis | Mainly atopic dermatitis |
In psoriasis
PSOARING 1 and 2 (NEJM, 2021) are two identical phase 3 trials in adults with mild-to-severe plaque psoriasis affecting 3–20% of body surface. The primary endpoint was clear or almost clear skin with at least a 2-grade improvement at week 12 [1]. In PSOARING 3 (JAAD, 2022) — 40 weeks of open-label continuation, 763 patients — 58.2% of those who entered the extension with plaques still visible (mild to severe) reached clear or almost clear skin [2].
The most interesting number is about carry-over. Patients who reached completely clear skin were taken off treatment and simply observed: the mean interval with no therapy at all before lesions returned was 130 days — close to four months. For a topical agent that is atypical: disease usually returns within weeks of stopping.
In atopic dermatitis
ADORING 1 and 2 (JAAD, 2024) are two phase 3 trials. Response was assessed on the vIGA-AD scale (clear or almost clear skin with at least a 2-grade improvement); a 75% or greater improvement in EASI was reached by 55.8% and 59.1% versus 22.9% and 21.2% [3]. In ADORING 3 (JAAD, 2025) — 48 weeks, 728 patients — 81.6% reached clear or almost clear skin at least once [4].
Where it sits in treatment
| Situation | Treatment |
|---|---|
| Psoriasis up to 20% of skin, mild to severe | Topical steroids, vitamin D analogues, tapinarof |
| Extensive psoriasis (more than 20% of skin) | Phototherapy, methotrexate, apremilast, deucravacitinib, biologics |
| Mild atopic dermatitis | Emollients, short steroid courses, calcineurin inhibitors |
| Moderate-to-severe atopic dermatitis | Emollients, short steroid courses, calcineurin inhibitors, tapinarof; if topical treatment is not enough — dupilumab and other systemic agents |
The niche for tapinarof is long-term topical treatment without steroids — where a steroid can no longer be used because the limit is spent, or could never be used because the site is the face, a fold, or a child.
How to use it
| Parameter | Detail |
|---|---|
| Formulation | 1% cream |
| Frequency | Once daily |
| Treated area | No formal limit |
| Body sites | Face, neck and folds included |
| Duration | No limit |
| Age | Psoriasis from 18, atopic dermatitis from 2 |
The pattern is not continuous application but intermittent: treat to clear skin → stop → observe → restart if lesions return. That is exactly how the long-term trials were built, and it is the schedule on which the off-therapy remission figures were obtained.
Who should see a doctor first
- Patients with substantially more than 20% of body surface involved: the issue is not safety but that topical therapy stops being practical.
- Psoriatic arthritis, pustular and erythrodermic psoriasis — systemic therapy is required: a topical agent has no effect on joints.
Adverse effects. Folliculitis is the main and most frequent reaction: 22.7% over a year in psoriasis and 12.1% over 48 weeks in atopic dermatitis. It appears as small inflamed papules at hair follicle openings, most often on covered skin. Usually mild to moderate and rarely a reason to stop — but it affects one patient in five, and the warning belongs before the first application.
- Contact dermatitis — 5.5% in psoriasis.
- Headache, nasopharyngitis, upper respiratory infections — within a few percent each.
In the atopic dermatitis trials, discontinuations due to adverse events were fewer on tapinarof than in the group receiving vehicle cream.
Bottom line
Tapinarof repairs the skin barrier and damps inflammation at the same time without causing atrophy — so it can be used for a long time, over any area and on the face. Two indications: plaque psoriasis in adults and atopic dermatitis from age 2; in those who reached completely clear skin, lesions took a mean of 130 days to return after stopping in psoriasis and 80 in eczema.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Lebwohl MG, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021;385(24):2219–2229. PMID 34879448
2. Strober B, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800–806. PMID 35772599
3. Silverberg JI, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457–465. PMID 38777187
4. Bissonnette R, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial. J Am Acad Dermatol. 2025;93(3):707–714. PMID 40383273
5. VTAMA (tapinarof) — US Prescribing Information, Organon.
Source: Tapinarof (VTAMA): The Non-Steroidal Cream You Can Use on the Face and for as Long as You Need — universum.earth. Dr. Pereligyn.
